Agilent Technologies has an average rating of overweight and mean price target of $181.89, according to analysts polled by FactSet.
John Crowley, president and CEO of the Washington, DC-based Biotechnology Innovation Organization, warned that overly broad investment restrictions could create uncertainty for innovators and ...
More Bonds of Agilent Technologies Inc. Moody’s Daily Credit Risk Score About the Agilent Technologies Inc.-Bond (US00846UAQ40) The Agilent Technologies Inc.-Bond has a maturity date of 9/9/2027 and ...
Financial News] NH Investment & Securities said Lunit could be revalued in terms of its business as a company in the AI drug-development value chain, rather than simply as an AI imaging diagnostics ...
NH Investment & Securities values Lunit's SCOPE AI pathology and biomarker business at more than 500 billion won, with 2027 ...
The United States' newly proposed rules to expand restrictions on outbound investment to China risk further politicizing and weaponizing bilateral economic and trade ties, market watchers and business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results